NasdaqCM:CORTPharmaceuticals
Does Corcept’s Raised Revenue Outlook and Buyback Boost the Bull Case for CORT?
Corcept Therapeutics recently reported its second quarter 2025 financial results, revised full-year revenue guidance to US$850–US$900 million, and completed a substantial share buyback program totaling more than US$146 million as of June 30, 2025.
The company's updates highlight ongoing profitability, management confidence, and efforts to support future growth through operational expansion and vendor partnerships.
We’ll explore how Corcept’s raised revenue guidance, fueled by its expanding...